Drug Profile
Orvepitant - NeRRe therapeutics
Alternative Names: 823296; GW 823296; GW823296XLatest Information Update: 11 Jul 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer NeRRe Therapeutics
- Class Amides; Antidepressants; Antipruritics; Antitussives; Anxiolytics; Piperidines; Pyrazines; Pyrroles
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cough; Pruritus
- Discontinued Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders
Most Recent Events
- 24 Jun 2022 Nerre Therapeutics initiates enrolment in a phase II trial for Cough in USA and United Kingdom (PO) (NCT05185089)
- 30 Jun 2020 Nerre Therapeutics completes a phase I trial of orvepitant in heathy volunteers in the UK (NCT04387981)
- 01 Jun 2020 Nerre Therapeutics initiates a phase I trial of orvepitant in heathy volunteers in the UK (NCT04387981)